Anti-ATPIF1 Rabbit Monoclonal Antibody for WB, IHC-P, IF/ICC, ELISA - Q9UII2

Core Product Specifications and Parameters

Biological Background: ATPIF1 Function and Localization

• ATPIF1 is an endogenous inhibitor of F(1)F(o)-ATP synthase that limits ATP depletion when mitochondrial membrane potential falls below a threshold, preventing the enzyme from acting as an ATP hydrolase (PubMed:35926043). Related references: PMID:35926043
• Indirectly regulates heme synthesis in erythroid tissues by modulating mitochondrial pH and redox potential, which facilitates ferrochelatase (FECH)-mediated iron insertion into protoporphyrin IX.
• Exclusively localized to the mitochondrion, with a nuclear-encoded precursor containing a cleavable transit peptide.
• Features a coiled-coil domain, undergoes alternative splicing, and is regulated by phosphorylation.
• The mature protein has a predicted molecular weight of approximately 12.2 kDa (UniProt Q9UII2), consistent with the ~12 kDa observed band.

Experimental Guidance and Technical Tips

• The immunogen (amino acids 26–106 of human ATPIF1) targets the mature protein exposed under native and denaturing conditions; the antibody is expected to detect both endogenous and recombinant ATPIF1.
• For Western blot, run reduced samples and expect a band near 12 kDa; include mitochondrial lysates as positive controls and standard loading controls.
• In IHC-P, antigen retrieval may be necessary; validate specificity using tissues with known ATPIF1 expression patterns.
• In IF/ICC, confirm mitochondrial localization by co-staining with established mitochondrial markers.
• ELISA applications can be developed by testing the antibody as capture or detection reagent; titrate and optimize for your specific assay conditions.

CamelBio: Your One-Stop Sourcing Bridge

CamelBio provides diagnostic manufacturers and research laboratories with seamless access to IVD raw materials like this ATPIF1 monoclonal antibody, supporting mitochondrial biology, energy metabolism, and hematological studies. Our comprehensive portfolio includes validated antibody pairs, optimized monoclonals and polyclonals, bulk ancillary reagents, and custom sourcing for rare targets, enabling you to advance projects from concept to clinic efficiently.